STUDY | **Efficacy of guselkumab in treating regional psoriasis and psoriatic arthritis: *post-hoc* analyses of VOYAGE 1 and 2**

Population: N = 335

Primary endpoint at W16 and W24:
- Scalp-specific Investigator's Global Assessment
- Hand and/or foot Physician's Global Assessment
- Fingernail Physician's Global Assessment
- Nail Psoriasis Severity Index
- Dermatology Life Quality Index

Eligibility: Enrolled in VOYAGE 1 and 2 trial; diagnosed with plaque psoriasis for ≥6 months with or without PsA; IGA ≥3; PASI ≥12; body surface affected by psoriasis ≥10%; self-reported PsA. ***Exclusion:*** *Prior use of guselkumab or adalimumab within last 3 months*

TRIAL DESIGN

Phase III randomized, placebo, active controlled VOYAGE 1 and 2 trials

Treatment arm 1 n = 153 — **Guselkumab** | 100 mg: W0, W4, then Q8W

Treatment arm 2 n = 106 — **Adalimumab** | 80 mg: W0 | 40 mg: W1, then Q8W

Control arm n = 76 — **Placebo**

Guselkumab | 100 mg: W16, W20, then Q8W

W0 — W16 — W24

EFFICACY W0–16

*vs control: p < 0.001 †vs control: p = 0.005

ss-IGA 0 or 1	80.6% *	66% *	22.7%
ss-IGA 0	63.6% *	55.3% *	16.7%
hf-PGA 0 or 1	68.9% *	61.3% *	14.8%
hf-PGA 0	55.6% *	35.5% †	7.4%
f-PGA 0 or 1	47.6% *	46.4% *	17%
f-PGA 0	10.7%	14.5%	6.4%
NAPSI	39.5% *	40.3% *	6.5%

Mean % improvement from baseline

NAPSI 0	18%	20.3%	6%
DLQI 0 or 1	45.6% *	30.5%	2.7%

EFFICACY W16–24

ss-IGA 0 or 1	77.5%	58.5%	p < 0.003
ss-IGA 0	62.8%	45.7%	p < 0.037
hf-PGA 0 or 1	66.7%	58.1%
hf-PGA 0	60%	48.4%
f-PGA 0 or 1	67%	60.9%
f-PGA 0	35%	21.7%
NAPSI	58%	59.5%

Mean % improvement from baseline

NAPSI 0	36%	31.1%
DLQI 0 or 1	47.7%	34.3%	p = 0.024

SAFETY

The types and frequencies of AEs in the PsA cohort were consistent with those reported for the overall studies.

Guselkumab offers deep and durable responses, with meaningful improvements in nail, scalp, and palmoplantar psoriasis in patients with psoriasis and PsA at Week 16 of treatment compared with placebo.

Abbreviations: AE, adverse event; DLQI, Dermatology Life Quality Index; f-PGA, fingernail Physician's Global Assessment; hf-PGA, hand and/or foot PGA; IGA, Investigator's Global Assessment ; NAPSI, Nail Psoriasis Area and Severity Index; PASI, Psoriasis Area and Severity Index; ss-IGA, scalp-specific IGA; PsA, psoriatic arthritis; Q8W, every 8 weeks; Q2W, every 2 weeks; W, week.

Orbai AM, et al. *Dermatol Ther (Heidelb).* 2023;13(11):2859-2868.

Psoriasis and Psoriatic Arthritis Hub | Brought to you by **Scientific Education Support**

This educational resource is supported through funds from pharmaceutical companies; a full list of our supporters can be found at psoriasis-hub.com. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.